Lypd6b depletion promotes CD8⁺ T cell-mediated anti-tumor immunity via metabolic reprogramming in colorectal cancer.

ABSTRACT: Lymphocyte antigen-plasminogen activator urokinase receptor domain-containing protein 6B (Lypd6b) is a newly identified molecule associated with neuromodulation. However, the role of Lypd6b in regulating the tumor microenvironment and its impact on CD8⁺ T cell-mediated antitumor immunity remain unknown. Here, we observe that Lypd6b expression is increased significantly in colorectal cancer (CRC) tumor tissues compared to normal tissues. Lypd6b is mainly expressed in CD8⁺ T cells in tumor tissues. Lypd6b knockout (Lypd6b^-/-) mice are resistant to AOM/DSS-induced tumorigenesis. Furthermore, global deficiency or CD8⁺ cell deficiency of Lypd6b inhibits MC38 or CMT-93 tumor growth and promotes the infiltration of CD8⁺ T cells. Mechanistical

SUBMITTER: Liu T 

PROVIDER: S-EPMC12820146 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature